CoChat
Sign Up
Cited by 166Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes

Open access
Mahapatra, Manoj Kumar, Karuppasamy, Muthukumar, Sahoo, Biswa Mohan·2022·Reviews in Endocrine and Metabolic Disorders
DOI 10.1007/s11154-021-09699-1PMC PMC8736331
Open this paper in CoChat — free accountOpen PDF

Abstract

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist). It has been approved as a second line treatment option for better glycaemic control in type 2 diabetes and currently under scrutiny for anti-obesity purpose. Semaglutide has been proved to be safe in adults and elderly patients with renal or hepatic disorders demanding no dose modification. Cardiovascular (CV) outcome trials established that it can reduce various CV risk factors in patients with established CV disorders. Semaglutide is well tolerated with no risk of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse effects. A large population affected with COVID-19 infection were diabetic; therefore use of semaglutide in diabetes as well as CV patients would be very much supportive in maintaining health care system during this pandemic situation. Hence, this peptidic drug can be truly considered as a quintessential of GLP-1 agonists for management of type 2 diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11154-021-09699-1

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Despite sharing a therapeutic class, individual GLP-1 RAs can exhibit diverse biological effects and safety profiles due to their distinct molecular structures and mechanisms of action.

    “This approach is grounded in the understanding that despite sharing a therapeutic class, individual GLP-1 RAs can exhibit diverse biological effects and safety profiles due to their distinct molecular structures and mechanisms of action [1,4,5,6].”

    From Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review (2024) · cites this paper as [4]

    The Introduction distinguishes exendin-based GLP-1 receptor agonists from GLP-1 analogues, and the Development section describes semaglutide’s structural modifications and their effects on drug stability and duration. The Clinical pharmacology section reports different efficacy outcomes for semaglutide and other GLP-1 receptor agonists. The paper does not establish that differences in safety profiles arise from distinct molecular structures or mechanisms of action; the Introduction instead says these agents were designed to act in the same way as GLP-1. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

  • Semaglutide has demonstrated significant utility in managing type 2 diabetes and obesity as a GLP-1 receptor agonist.

    “The drug has demonstrated significant utility in managing type 2 diabetes and obesity, thanks to its action as a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) [4,5,6].”

    From Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review (2024) · cites this paper as [4]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 58

  1. [1]Garber AJ Abrahamson MJ Barzilay JI Blonde L Bloomgarden ZT Bush MA Dagogo-Jack S DeFronzo RA Einhorn D Fonseca VA Garber JR Garvey WT Grunberger G Handelsman Y Hirsch IB Jellinger PS McGill JB Mechanick JI Rosenblit PD Umpierrez GE Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm–2017 Executive Summary Endocr Pract 2017 23 2 207 238 10.4158/EP161682.CS 28095040 · DOI · Paper page
  2. [2]Inzucchi SE Bergenstal RM Buse JB Diamant M Ferrannini E Nauck M Peters AL Tsapas A Wender R Matthews DR Management of hyperglycemia in type 2 diabetes 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 140 149 10.2337/dc14-2441 25538310 · DOI · Paper page
  3. [4]Astrup A Finer N Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000 1 2 57 59 10.1046/j.1467-789x.2000.00013.x 12119987 · DOI
  4. [5]Mauricio D Meneghini L Seufert J Liao L Wang H Tong L Cali A Stella P Carita P Khunti K Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA Diabetes Obes Metab 2017 19 8 1155 1164 10.1111/dom.12927 28251792 PMC5573947 · DOI
  5. [6]Tasyurek HM Altunbas HA Balci MK Sanlioglu S Incretins: Their physiology and application in the treatment of diabetes mellitus Diabetes Metab Res Rev 2014 30 354 371 10.1002/dmrr.2501 24989141 · DOI · Paper page
  6. [7]Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 10.1016/S0140-6736(06)69705-5 17098089 · DOI · Paper page
  7. [9]Knop FK Brønden A Vilsbøll T Exenatide: pharmacokinetics clinical use and future directions Expert Opin Pharmacother 2017 18 6 555 571 10.1080/14656566.2017.1282463 28085521 · DOI
  8. [10]Leon N LaCoursiere R Yarosh D Patel RS Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes Pharm Ther 2017 42 11 676 682 PMC5642155 29089722
  9. [11]Buse JB Nauck M Forst T Sheu WH Shenouda SK Heilmann CR Hoogwerf BJ Gao A Boardman MK Fineman M Porter L Schernthaner G Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised open-label study Lancet 2013 381 9861 117 124 10.1016/S0140-6736(12)61267-7 23141817 · DOI · Paper page
  10. [12]Smith LL Mosley JF 2nd Parke C Brown J Barris LS Phan LD Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist Pharm Ther 2016 41 6 357 360 PMC4894510 27313432
  11. [13]Billings LK Handelsman Y Heile M Schneider D Wyne K Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus J Manag Care Spec Pharm. 2018 24 9-a Suppl S30 S41 10.18553/jmcp.2018.24.9-a.s30 30156447 PMC10408424 · DOI
  12. [17]Novo Nordisk. Press Release: Ozempic® approved in Canada for the treatment of adults with type 2 diabetes. 2018. https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/Ozempic%20press%20release_Eng_01.08.2018_FINAL.pdf. Assessed 1 May 2020.
  13. [18]Novo Nordisk. Press Release: Health Canada approves RYBELSUS® (semaglutide tablets) the first and only GLP-1 analogue in a pill for the treatment of adults with type 2 diabetes. 2020. https://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/News/Health-Canada-approves-RYBELSUS-semaglutide-tablets-FINAL-April-9-EN.pdf. Assessed 5 May 2020.
  14. [24]Deacon CF Knudsen LB Madsen K Wiberg FC Jacobsen O Holst JJ Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity Diabetologia 1998 41 3 271 278 10.1007/s001250050903 9541166 · DOI
  15. [25]Knudsen LB Nielsen PF Huusfeldt PO Johansen NL Madsen K Pedersen FZ Thøgersen H Wilken M Agersø H Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 2000 43 9 1664 1669 10.1021/jm9909645 10794683 · DOI
  16. [26]Knudsen LB Lau J The Discovery and Development of Liraglutide and Semaglutide Front Endocrinol (Lausanne) 2019 10 155 10.3389/fendo.2019.00155 31031702 PMC6474072 · DOI · Paper page
  17. [27]Lau J Bloch P Schäffer L Pettersson I Spetzler J Kofoed J Madsen K Knudsen LB McGuire J Steensgaard DB Strauss HM Gram DX Knudsen SM Nielsen FS Thygesen P Reedtz-Runge S Kruse T Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide J Med Chem 2015 58 18 7370 7380 10.1021/acs.jmedchem.5b00726 26308095 · DOI · Paper page
  18. [28]Ahmann AJ Capehorn M Charpentier G Dotta F Henkel E Lingvay I Holst AG Annett MP Aroda VR Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week Open-Label Randomized Clinical Trial Diabetes Care 2018 41 2 258 266 10.2337/dc17-0417 29246950 · DOI · Paper page
  19. [29]Twarog C Fattah S Heade J Maher S Fattal E Brayden DJ Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10) Pharmaceutics 2019 11 2 78 10.3390/pharmaceutics11020078 PMC6410172 30781867 · DOI
  20. [30]Fonseca VA Capehorn MS Garg SK Jódar Gimeno E Hansen OH Holst AG Nayak G Seufert J Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide J Clin Endocrinol Metab 2019 104 2 4078 4086 10.1210/jc.2018-02685 30938762 · DOI
  21. [32]Romera I Cebrián-Cuenca A Álvarez-Guisasola F Gomez-Peralta F Reviriego J A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes Diabetes Ther 2019 10 1 5 19 10.1007/s13300-018-0535-9 30506340 PMC6349277 · DOI · Paper page
  22. [37]Jensen L Kupcova V Arold G Pettersson J Hjerpsted JB Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment Diabetes Obes Metab 2018 20 4 998 1005 10.1111/dom.13186 29205786 PMC5873441 · DOI
  23. [38]Korsatko S Jensen L Brunner M Sach-Friedl S Tarp MD Holst AG Heller SR Pieber TR Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized placebo-controlled double-blind crossover trial Diabetes Obes Metab 2018 20 11 2565 2573 10.1111/dom.13422 29893488 PMC6221089 · DOI · Paper page
  24. [39]Beglinger C Poller B Arbit E Ganzoni C Gass S Gomez-Orellana I Drewe J Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects Clin Pharmacol Ther 2008 84 4 468 474 10.1038/clpt.2008.35 19238651 · DOI
  25. [40]Granhall C Donsmark M Blicher TM Golor G Søndergaard FL Thomsen M Bækdal TA Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue Oral Semaglutide in Healthy Subjects and Subjects with Type 2 Diabetes Clin Pharmacokinet 2019 58 6 781 791 10.1007/s40262-018-0728-4 30565096 · DOI · Paper page
  26. [44]Granhall C Søndergaard FL Thomsen M Anderson TW Pharmacokinetics Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment Clin Pharmacokinet 2018 57 12 1571 1580 10.1007/s40262-018-0649-2 29623579 PMC6267549 · DOI
  27. [45]Baekdal TA Thomsen M Kupčová V Hansen CW Anderson TW Pharmacokinetics Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment J Clin Pharmacol 2018 58 10 1314 1323 10.1002/jcph.1131 29693715 PMC6175428 · DOI
  28. [48]Davies M Pieber TR Hartoft-Nielsen ML Hansen OKH Jabbour S Rosenstock J Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial JAMA 2017 318 15 1460 1470 10.1001/jama.2017.14752 29049653 PMC5817971 · DOI · Paper page
  29. [49]Sorli C Harashima SI Tsoukas GM Unger J Karsbøl JD Hansen T Bain SC Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind randomised placebo-controlled parallel-group multinational multicentre phase 3a trial Lancet Diabetes Endocrinol 2017 5 4 251 260 10.1016/S2213-8587(17)30013-X 28110911 · DOI · Paper page
  30. [51]Aroda VR Bain SC Cariou B Piletič M Rose L Axelsen M Rowe E DeVries JH Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised open-label parallel-group multicentre multinational phase 3a trial Lancet Diabetes Endocrinol 2017 5 5 355 366 10.1016/S2213-8587(17)30085-2 28344112 · DOI · Paper page
  31. [54]Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A, SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised open-label phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–86. 10.1016/S2213-8587(18)30024-X. 29397376 · DOI · Paper page
  32. [55]Lingvay I Catarig AM Frias JP Kumar H Lausvig NL le Roux CW Thielke D Viljoen A McCrimmon RJ Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind phase 3b randomised controlled trial Lancet Diabetes Endocrinol 2019 7 11 834 844 10.1016/S2213-8587(19)30311-0 31540867 · DOI · Paper page
  33. [58]Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9. 10.1016/j.diabet.2019.101117. 31539622 · DOI · Paper page
  34. [59]Seino Y Terauchi Y Osonoi T Yabe D Abe N Nishida T Zacho J Kaneko S Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes Diabetes Obes Metab 2018 20 2 378 388 10.1111/dom.13082 28786547 PMC5813234 · DOI · Paper page
  35. [60]Kaku K Yamada Y Watada H Abiko A Nishida T Zacho J Kiyosue A Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial Diabetes Obes Metab 2018 20 5 1202 1212 10.1111/dom.13218 29322610 PMC5969242 · DOI · Paper page
  36. [66]Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK, Christiansen E, Hertz CL, Haluzík M, PIONEER 1 Investigators. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724–32. 10.2337/dc19-0749. 31186300 · DOI · Paper page
  37. [67]Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E, PIONEER 2 Investigators. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019;42(12):2272–81. 10.2337/dc19-0883. 31530666 · DOI · Paper page
  38. [68]Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M, PIONEER 3 Investigators. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults with Type 2 Diabetes Uncontrolled with Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019;321(15):1466–80. 10.1001/jama.2019.2942. PMC6484814 30903796 · DOI · Paper page
  39. [71]Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC, PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841–51. 10.1056/NEJMoa1901118. 31185157 · DOI · Paper page
  40. [72]Bain SC Mosenzon O Arechavaleta R Bogdanski P Comlekci A Consoli A Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale design and patient baseline characteristics for the PIONEER 6 trial Diabetes Obes Metab 2019 21 499 508 10.1111/dom.13553 30284349 PMC6587508 · DOI
  41. [74]Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E, PIONEER 8 Investigators. Efficacy Safety and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019;42(12):2262–71. 10.2337/dc19-0898. PMC7364672 31530667 · DOI · Paper page
  42. [76]Yabe D, Nakamura J, Kaneto H, Deenadayalan S, Navarria A, Gislum M, Inagaki N, PIONEER 10 Investigators. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label randomised active-controlled phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392–406. 10.1016/S2213-8587(20)30074-7. 32333876 · DOI · Paper page
  43. [80]Davies MJ D'Alessio DA Fradkin J Kernan WN Mathieu C Mingrone G Rossing P Tsapas A Wexler DJ Buse JB Management of Hyperglycemia in Type 2 Diabetes 2018 A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2018 41 12 2669 2701 10.2337/dci18-0033 30291106 PMC6245208 · DOI · Paper page
  44. [81]American Diabetes Association 9 Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020 Diabetes Care 2020 43 Suppl 1 S98 S110 10.2337/dc20-S009 31862752 · DOI · Paper page
  45. [82]Gomez-Peralta F Abreu C Profile of semaglutide in the management of type 2 diabetes: design development and place in therapy Drug Des Devel Ther 2019 13 731 738 10.2147/DDDT.S165372 30863012 PMC6388990 · DOI
  46. [85]Brunton SA Mosenzon O Wright EE Jr Integrating oral semaglutide into clinical practice in primary care: for whom when and how? Postgrad Med 2020 132 sup2 48 60 10.1080/00325481.2020.1798162 32815453 · DOI
  47. [88]Tan X Cao X Zhou M Zou P Hu J Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes Expert Opin Investig Drugs 2017 26 9 1083 1089 10.1080/13543784.2017.1360274 28741970 · DOI
  48. [89]O'Neil PM Birkenfeld AL McGowan B Mosenzon O Pedersen SD Wharton S Carson CG Jepsen CH Kabisch M Wilding JPH Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised double-blind placebo and active controlled dose-ranging phase 2 trial Lancet 2018 392 10148 637 649 10.1016/S0140-6736(18)31773-2 30122305 · DOI · Paper page
  49. [90]Vilsbøll T Bain SC Leiter LA Lingvay I Matthews D Simó R Helmark IC Wijayasinghe N Larsen M Semaglutide reduction in glycated haemoglobin and the risk of diabetic retinopathy Diabetes Obes Metab 2018 20 4 889 897 10.1111/dom.13172 29178519 PMC5888154 · DOI · Paper page
  50. [92]Riehle C Abel ED Insulin Signaling and Heart Failure Circ Res 2016 118 7 1151 1169 10.1161/CIRCRESAHA.116.306206 27034277 PMC4833475 · DOI
  51. [93]Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso García Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016;2(3):200–5. 10.1093/ehjcvp/pvw007. PMC4907355 27418973 · DOI
  52. [96]Iorga RA Bacalbasa N Carsote M Bratu OG Stanescu AMA Bungau S Pantis C Diaconu CC Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review) Exp Ther Med 2020 20 3 2396 2400 10.3892/etm.2020.8714 32765722 PMC7401476 · DOI
  53. [101]Kapitza C Nosek L Jensen L Hartvig H Jensen CB Flint A Semaglutide a once-weekly human GLP-1 analog does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel J Clin Pharmacol 2015 55 5 497 504 10.1002/jcph.443 25475122 PMC4418331 · DOI · Paper page
  54. [102]Hausner H Derving Karsbøl J Holst AG Jacobsen JB Wagner FD Golor G Anderson TW Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects Clin Pharmacokinet 2017 56 11 1391 1401 10.1007/s40262-017-0532-6 28349387 PMC5648738 · DOI · Paper page
  55. [103]Bækdal TA Borregaard J Hansen CW Thomsen M Anderson TW Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril Warfarin Digoxin and Metformin in Healthy Subjects Clin Pharmacokinet 2019 58 9 1193 1203 10.1007/s40262-019-00756-2 30945118 PMC6719321 · DOI
  56. [104]Jordy AB Albayaty M Breitschaft A Anderson TW Christiansen E Houshmand-Øregaard A Manigandan E Bækdal TA Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects Clin Pharmacokinet 2021 60 1171 1185 10.1007/s40262-020-00976-x 33782832 PMC8416862 · DOI
  57. [105]Bækdal TA Breitschaft A Navarria A Hansen CW A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide Expert Opin Drug Metab Toxicol 2018 14 8 869 877 10.1080/17425255.2018.1488965 29897249 · DOI
  58. [106]Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Bækdal T. SAT-140 A Drug-Drug Interaction Trial of Oral Semaglutide with Levothyroxine and Multiple Coadministered Tablets. J Endocr Soc. 2019;3(Suppl 1):SAT-140. 10.1210/js.2019-SAT-140. · DOI

Cited by

Sorted by citations

Authors
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M.
Affiliations
Roland Institute of Pharmaceutical Sciences (IN)
Corresponding author
Mahapatra, Manoj Kumar
ORCID
Venue
Reviews in Endocrine and Metabolic Disorders
Publisher
Springer Science and Business Media LLC
Published
2022-01-07
Volume
23
Issue
3
Pages
521-539
ISSN
  • 1389-9155 (ISSN-L)
  • 1573-2606
DOI
10.1007/s11154-021-09699-1
PMC
PMC8736331
OpenAlex
W4205983920
Cited by
166
References
20
Citations by year
2026: 31 · 2025: 57 · 2024: 48 · 2023: 22 · 2022: 7
FWCI
4.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Reviews in Endocrine and Metabolic Disorders (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
semaglutide, GLP-1 receptor agonists, type 2 diabetes, cardiovascular risk reduction, oral GLP-1 receptor agonists, glycemic control, anti-obesity, drug safety, gastrointestinal adverse effects, COVID-19 pandemic, renal and hepatic impairment
MeSH terms
Glucagon-Like Peptide-1 Receptor, COVID-19 Drug Treatment, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review